Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
Get Alerts APLS Hot Sheet
Join SI Premium – FREE
WALTHAM, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will participate in the following May investor conferences:
- BofA Securities 2025 Healthcare Conference: Fireside chat on Tuesday, May 13, 2025 at 8:40 a.m. PT
- Stifel 2025 Virtual Ophthalmology Forum: Fireside chat on Tuesday, May 27, 2025 at 2:30 p.m. ET
The live conference webcasts will be posted on the “Events and Presentations” page of the “Investors and Media” section of the company’s website. A replay of the webcasts will be available for approximately 90 days following the event.
About Apellis
Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that combines courageous science and compassion to develop life-changing therapies for some of the most challenging diseases patients face. We ushered in the first new class of complement medicine in 15 years and now have two approved medicines targeting C3. These include the first-ever therapy for geographic atrophy, a leading cause of blindness around the world. We believe we have only begun to unlock the potential of targeting C3 across many serious diseases. For more information, please visit http://apellis.com or follow us on Twitter and LinkedIn.
Investor Contact:
Neil Carnahan
[email protected]
207.318.4494
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Service CU Impact Foundation Awards $110,000 in Scholarships
- Indiana American Water and American Water Charitable Foundation Support Disaster Recovery Efforts Across Indiana
- Crypto Presale Price Prediction 2026: What Makes MemeToro Different From Standard Memecoin Presales?
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesRelated Entities
TwitterSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share